NCT02638402

Brief Summary

To clarify the critical role of glycosyltransferases, altered Mucins, and RTKs in human ovarian and endometrial neoplasms, the study will examine the immunohistochemical expression profiles of glycosyltransferases, Mucins and receptor tyrosin kinases (RTKs) family in various stages and/or histologic subtypes of human ovarian and endometrial neoplasms and tissue microarrays.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2016

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 20, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 23, 2015

Completed
4 months until next milestone

Study Start

First participant enrolled

May 1, 2016

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2016

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

May 13, 2016

Status Verified

May 1, 2016

Enrollment Period

3 months

First QC Date

December 20, 2015

Last Update Submit

May 11, 2016

Conditions

CarcinogenesisOvarian CancerEndometrial Cancer

Keywords

glycosylationmucinreceptor tyrosin kinasesovarian cancerendometrial cancer

Outcome Measures

Primary Outcomes (1)

  • Measure the Immunohistochemistry (IHC) expression

    5 years after patient received surgery

Study Arms (2)

Stage I, II, III, IV ovarian cancer

Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital

Stage I, II, III, IV endometrial cancer

Stage I, II, III, IV endometrial cancer receive treatment in National Taiwan University Hospital

Eligibility Criteria

Age20 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Ovarian and endometrial cancer patients receiving operation in National Taiwan University Hospital

You may qualify if:

  • Ovarian and endometrial cancer patients receiving operation in National Taiwan University Hospital

You may not qualify if:

  • Recurrence or non-operable patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

CarcinogenesisOvarian NeoplasmsEndometrial NeoplasmsMedullary cystic kidney disease 1

Condition Hierarchy (Ancestors)

Neoplastic ProcessesNeoplasmsPathologic ProcessesPathological Conditions, Signs and SymptomsEndocrine Gland NeoplasmsNeoplasms by SiteOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal DisordersUterine NeoplasmsUterine Diseases

Study Officials

  • Chi-Hau Chen, MD, PhD

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chi-Hau Chen, MD, PhD

CONTACT

+886-972651980chihau@ntuh.gov.tw

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 20, 2015

First Posted

December 23, 2015

Study Start

May 1, 2016

Primary Completion

August 1, 2016

Study Completion

August 1, 2017

Last Updated

May 13, 2016

Record last verified: 2016-05

Data Sharing

IPD Sharing
Will not share